The pharmacological fields most explored in the past decade have been neurodegenerative disorders, especially Alzheimer’s or Parkinson’s diseases, due to interaction with AChE and MAO-B, respectively, but also including effects on inflammation or on the cardiovascular system, and in the field of chemotherapeutic agents, with special attention to different types of cancer. The gene discussed is MAOB; the disease is Parkinson disease.